CU20220020A7 - Muteínas derivadas de la interleucina-2 humana con actividad superagonista - Google Patents

Muteínas derivadas de la interleucina-2 humana con actividad superagonista

Info

Publication number
CU20220020A7
CU20220020A7 CU2022000020A CU20220020A CU20220020A7 CU 20220020 A7 CU20220020 A7 CU 20220020A7 CU 2022000020 A CU2022000020 A CU 2022000020A CU 20220020 A CU20220020 A CU 20220020A CU 20220020 A7 CU20220020 A7 CU 20220020A7
Authority
CU
Cuba
Prior art keywords
receptor
beta chain
superagonist
human interleukin
variants
Prior art date
Application number
CU2022000020A
Other languages
English (en)
Other versions
CU24775B1 (es
Inventor
Portilla Tania Carmenate
Monzón Kalet León
Hernández Ernesto Relova
Dorantes Gertrudis Rojas
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2022000020A priority Critical patent/CU24775B1/es
Priority to CN202380028285.7A priority patent/CN118891275A/zh
Priority to PCT/CU2023/050001 priority patent/WO2023174457A1/es
Priority to CA3246211A priority patent/CA3246211A1/en
Priority to KR1020247034148A priority patent/KR20240158345A/ko
Priority to US18/842,562 priority patent/US20250179139A1/en
Priority to JP2024555119A priority patent/JP2025510653A/ja
Priority to EP23721588.4A priority patent/EP4495134A1/en
Priority to AU2023235251A priority patent/AU2023235251A1/en
Priority to MX2024011066A priority patent/MX2024011066A/es
Priority to ARP230100668A priority patent/AR128822A1/es
Priority to TW112108466A priority patent/TW202400630A/zh
Publication of CU20220020A7 publication Critical patent/CU20220020A7/es
Priority to ZA2024/07182A priority patent/ZA202407182B/en
Priority to CONC2024/0013508A priority patent/CO2024013508A2/es
Publication of CU24775B1 publication Critical patent/CU24775B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>La presente invención se relaciona con Ia rama de Ia Biotecnología, y se basa en Ia identificación de conjuntos de mutaciones de IL-2 en las proximidades de Ia interfaz con Ia cadena beta de su receptor, a través de Ia selección de variantes provenientes de bibliotecas sobre fagos filamentosos por afinidad al dominio extracelular de Ia cadena beta. Las proteínas recombinantes derivadas de estas variantes muestran un perfil de desarrollabilidad muy favorable, en cuanto a sus altos niveles de expresión, baja tendencia a Ia agregación, y alta estabilidad térmica. Además, en comparación con Ia IL-2 original no mutada, y con otras muteínas superagonistas descritas, tienen una mayor capacidad de estimulación de las poblaciones efectoras del sistema inmune que portan el receptor dimérico de Ia IL-2 y una mayor actividad anti-tumoral <em>in vivo.</em></p>
CU2022000020A 2022-03-18 2022-03-18 Muteínas derivadas de la interleucina-2 humana con actividad superagonista CU24775B1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CU2022000020A CU24775B1 (es) 2022-03-18 2022-03-18 Muteínas derivadas de la interleucina-2 humana con actividad superagonista
EP23721588.4A EP4495134A1 (en) 2022-03-18 2023-03-15 Human interleukin-2-derived muteins with superagonist activity
AU2023235251A AU2023235251A1 (en) 2022-03-18 2023-03-15 Human interleukin-2-derived muteins with superagonist activity
CA3246211A CA3246211A1 (en) 2022-03-18 2023-03-15 MUTEINS DERIVED FROM HUMAN INTERLEUKIN-2 WITH SUPERAGONIC ACTIVITY
KR1020247034148A KR20240158345A (ko) 2022-03-18 2023-03-15 슈퍼작용제 활성을 가지는 인간 인터루킨-2 유래 뮤테인
US18/842,562 US20250179139A1 (en) 2022-03-18 2023-03-15 Human interleukin-2-derived muteins with superagonist activity
JP2024555119A JP2025510653A (ja) 2022-03-18 2023-03-15 スーパーアゴニスト活性を有するヒトインターロイキン２由来ムテイン
CN202380028285.7A CN118891275A (zh) 2022-03-18 2023-03-15 具有超激动剂活性的人白细胞介素-2衍生的突变蛋白
PCT/CU2023/050001 WO2023174457A1 (es) 2022-03-18 2023-03-15 Muteínas derivadas de la interleucina-2 humana con actividad superagonista
MX2024011066A MX2024011066A (es) 2022-03-18 2023-03-15 Muteinas derivadas de la interleucina-2 humana con actividad superagonista.
ARP230100668A AR128822A1 (es) 2022-03-18 2023-03-17 Muteínas derivadas de la interleucina-2 humana con actividad superagonista
TW112108466A TW202400630A (zh) 2022-03-18 2023-03-17 具有超級促效劑活性之人介白素２衍生的突變蛋白
ZA2024/07182A ZA202407182B (en) 2022-03-18 2024-09-19 Human interleukin-2-derived muteins with superagonist activity
CONC2024/0013508A CO2024013508A2 (es) 2022-03-18 2024-10-03 Muteínas derivadas de la interleucina-2 humana con actividad superagonista

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2022000020A CU24775B1 (es) 2022-03-18 2022-03-18 Muteínas derivadas de la interleucina-2 humana con actividad superagonista

Publications (2)

Publication Number Publication Date
CU20220020A7 true CU20220020A7 (es) 2023-12-07
CU24775B1 CU24775B1 (es) 2026-01-12

Family

ID=86328873

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000020A CU24775B1 (es) 2022-03-18 2022-03-18 Muteínas derivadas de la interleucina-2 humana con actividad superagonista

Country Status (14)

Country Link
US (1) US20250179139A1 (es)
EP (1) EP4495134A1 (es)
JP (1) JP2025510653A (es)
KR (1) KR20240158345A (es)
CN (1) CN118891275A (es)
AR (1) AR128822A1 (es)
AU (1) AU2023235251A1 (es)
CA (1) CA3246211A1 (es)
CO (1) CO2024013508A2 (es)
CU (1) CU24775B1 (es)
MX (1) MX2024011066A (es)
TW (1) TW202400630A (es)
WO (1) WO2023174457A1 (es)
ZA (1) ZA202407182B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24483B1 (es) 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
TW202115105A (zh) 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
WO2021222150A2 (en) * 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Also Published As

Publication number Publication date
AR128822A1 (es) 2024-06-19
AU2023235251A1 (en) 2024-10-17
CU24775B1 (es) 2026-01-12
EP4495134A1 (en) 2025-01-22
CO2024013508A2 (es) 2024-10-31
US20250179139A1 (en) 2025-06-05
KR20240158345A (ko) 2024-11-04
MX2024011066A (es) 2024-09-23
ZA202407182B (en) 2025-05-28
JP2025510653A (ja) 2025-04-15
CA3246211A1 (en) 2025-03-07
TW202400630A (zh) 2024-01-01
CN118891275A (zh) 2024-11-01
WO2023174457A1 (es) 2023-09-21

Similar Documents

Publication Publication Date Title
Potere et al. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study
Angileri et al. Molecular mimicry may explain multi-organ damage in COVID-19
Bergsten et al. Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study
Gabbay et al. Immune system dysregulation in adolescent major depressive disorder
Stephen-Victor et al. IL-26: an emerging proinflammatory member of the IL-10 cytokine family with multifaceted actions in antiviral, antimicrobial, and autoimmune responses
CL2020000531A1 (es) Construcciones con un dominio sirp-alfa o sus variantes. (divisional solicitud 201800340)
CU20220020A7 (es) Muteínas derivadas de la interleucina-2 humana con actividad superagonista
Kim et al. Identification of a novel angiogenic peptide from periostin
Jeon et al. Ohmyungsamycin promotes M1-like inflammatory responses to enhance host defence against Mycobacteroides abscessus infections
Li et al. Interleukin‐27 enhances the production of tumour necrosis factor‐α and interferon‐γ by bone marrow T lymphocytes in aplastic anaemia
Gutierrez et al. A incidência dos sintomas de depressão pós-parto durante a pandemia de COVID-19: The incidence of postpartum depression symptoms during the COVID-19 pandemic
Vincent et al. The sepsis text
Kupsa et al. Serum levels of soluble adhesion molecules in newly diagnosed acute myeloid leukemia and in complete remission suggest endothelial cell activation by myeloblasts
BR112023004860A2 (pt) Construto de interleucina 15 (il15), composição farmacêutica, método de tratamento de câncer e método para aumentar a sobrevivência de uma célula imune
Wunderink Adjunctive therapy in community-acquired pneumonia
MX2024015497A (es) Nuevos peptidos como antagonistas selectivos del receptor de la il-23
Tralongo et al. Granulocyte colony-stimulating factors (G-CSF) and COVID-19: A double-edged sword
Neurath New therapies for sepsis: focus on the interleukin (IL) 12 family member IL27
AR093391A1 (es) POLIPEPTIDOS DERIVADOS DEL TGFb Y SUS USOS
Savaşan et al. Parvovirus B19 infection and acute lymphoblastic leukaemia.
Nimri et al. Severe neutropenia complicated with necrotizing fasciitis unveils a diagnosis of rheumatoid arthritis: a case report
Motuzova et al. Development and certification of an industrial reference standard for determination of filgrastim activity
Boehning Protein S-acylation as a New Paradigm in Cell Signaling
Elizarraras-Rivas et al. Serum levels of anti-Ro52/TRIM21 antibodies in SARS-CoV-2 genetic variants and long COVID. Beyond their application in autoimmune diseases
Bayhan et al. Bacteremia caused by Rothia mucilaginosa after pneumonia, in a patient with hematopoietic stem cell transplantation